Hemab, still playing coy, gets its first major fundraise for hemophilia bispecifics
A company seeded by Novo’s incubator at the end of 2020 is taking its next step Thursday, emerging into the hemophilia space with a hefty Series A.
The Danish biotech Hemab is putting the bow on a $55 million round early Thursday, raised with money from Novo Seeds as well as prominent investor RA Capital. Seeing RA invest as early as a Series A raises the natural suspicion of a potential IPO, and newly-appointed CEO Benny Sorensen told Endpoints News he’d hoped to be asked about it.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.